- Previous Close
5,376.05 - Open
5,301.00 - Bid 5,340.40 x --
- Ask 5,344.05 x --
- Day's Range
5,274.60 - 5,382.45 - 52 Week Range
4,407.05 - 6,439.90 - Volume
18,255 - Avg. Volume
266,478 - Market Cap (intraday)
638.967B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
30.12 - EPS (TTM)
177.41 - Earnings Date Feb 7, 2025 - Feb 11, 2025
- Forward Dividend & Yield 10.00 (0.18%)
- Ex-Dividend Date Aug 9, 2024
- 1y Target Est
5,777.67
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.
www.alkemlabs.com17,432
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ALKEM.NS
View MorePerformance Overview: ALKEM.NS
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALKEM.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALKEM.NS
View MoreValuation Measures
Market Cap
642.79B
Enterprise Value
610.17B
Trailing P/E
30.29
Forward P/E
25.64
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.15
Price/Book (mrq)
5.59
Enterprise Value/Revenue
4.89
Enterprise Value/EBITDA
21.58
Financial Highlights
Profitability and Income Statement
Profit Margin
16.13%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
127.32B
Net Income Avi to Common (ttm)
20.54B
Diluted EPS (ttm)
177.41
Balance Sheet and Cash Flow
Total Cash (mrq)
42.7B
Total Debt/Equity (mrq)
13.24%
Levered Free Cash Flow (ttm)
--